

**CA 125; OVARIAN
CANCER MARKER , SERUM
(CMIA)**

U/mL

< 35.00

Note: 1. This test is not recommended to screen Ovarian cancer in the general population.

2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy

3. Patients with confirmed Ovarian cancer may show normal pre-treatment

CA 125 levels. Hence this assay, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The assay value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures.

Clinical Use

- An aid in the management of Ovarian cancer patients. Preoperative CA 125 level of < 65 U /mL is associated with a significantly greater 5 year survival rate.
- Monitor the course of disease in patients with Invasive epithelial ovarian cancer
- Detection of residual tumor in patients with Primary epithelial ovarian cancer who have undergone first line therapy. Persistent elevation of CA 125 levels after 3 cycles of therapy indicates a poor prognosis.

STAGE OF OVARIAN CANCER	PERCENTAGE POSITIVITY OF CA 125
Stage I	50
Stage II	90
Stage III & IV	>90

Increased Levels

- Primary epithelial ovarian carcinoma
- Healthy individuals (1-2 %)
- First trimester of pregnancy
- Follicular phase of menstrual cycle
- Non malignant conditions – Cirrhosis, Hepatitis, Endometriosis, Ovarian cysts, Pelvic Inflammatory disease
- Non Ovarian malignancies - Endometrial, Pancreatic, Lung, Breast, Colorectal & other Gastrointestinal tumors.